Another interesting long covid case study

New Post Public Reply Private Reply Replies (0) Message Board
redspeed
286
Another interesting long covid case study developing...

If you had Long Covid for 25 months

were at wits end and separately tried paxlovid

keep in mind you were one of the ones that could without the drug interactions and other issue...

and it didn't work

what do you do?

Try Tollovid?

So you try Tollovid

"Tollovid is taken 4 times a day. Within hours of my first Tollovid dose, I felt better. After dose 2, I felt as well as I had on Paxlovid. This morning, I took my resting heart rate and checked my O2 upon waking. Rhr was 57. O2 was 98, lying down."

"I have not seen such good numbers in 2 years of Long Covid. Not even on Paxlovid. My temperature has begun coming down, too. It was 99.9 during Paxlovid rebound. Has been between 98.3 and 99.2 today."

"While my resting heart rate during the Paxlovid rebound was 111 sitting still, my peak exercising heart rate today on Tollovid was 109. My recovery rate was also phenomenal. Within 5 minutes, it was back to 72. That has never happened in 25 months of Long Covid."

So who would try to get in the way of a company that has potential solution to either covid sufferers or long covid?

What possess someone to wish death and suffering on so many?

History has a very short list with many duplicates

JPutin, what you do, what you become, is not my concern. Dozens of fake IDs. Did you tell Ann and Tonya yet who is the real you? It would be better coming from you them me, eh?

Would you recommend a nice letter, email or phone call?

The world is full of so-called "men" like you, and, in a perfect world, everything we do comes with a price, but this ain't a perfect world.

People do bad things. If you're lucky, you get a chance to set it right, but most of the time it goes unpunished.

Is this not one of those times?

The one analyst that was jailed, never recovered. Took a big bite of the apple I guess.

I hear the other analyst lived his remaining years in despair suffering from long covid.

Were they an anti masker?

Were they an anti vaxer?

Or were they just and anti Gerald?

Did the family turn to controlled dangerous substances to cope?

Court records say yes, but let's not let facts get in the way of a good story.

Nothing personal with my lawsuit that is coming.

I really thought, as did others, you were a certified stock analyst on earnings calls so I'm suing for damages while the law of statute remain.

It will cost you about $20K to define, but millions if we win.

Please don't lose all my money on $MONI

I suspect, damages when others join in, will be in the tens of millions

That minimum wage job is going to take 500 years to pay us back oh smart one





Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 127

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 184

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 342

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 342

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Genmab's Ongoing Share Buy-back Program Details and Impact

Updated Category News Views 119

Introduction to the Share Buy-back Program In a recent announcement, Genmab A/S (NASDAQ: GMAB) revealed that it has initiated an ambitious share buy-back program. This initiative aims to repurchase up to 2.2 million shares, which is a strategic step not just to reduce capital but also to fulfill commitments under the Restricted Stock Unit program. The company anticipates...

Continue Reading
Allego Strengthens Leadership with New Innovative CTO

Updated Category News Views 159

Allego Appoints Holger Riemenschneider as Chief Technology Officer Allego N.V. (NASDAQ: ALGO) has recently appointed Holger Riemenschneider as its Chief Technology Officer. This move is a significant step for the company, which has rapidly established itself as a leading name in the electric vehicle (EV) charging industry. With Holger on board, Allego is looking to...

Continue Reading
Exploring the Growth Drivers of Semiconductor Fabrication Software

Updated Category News Views 167

Understanding the Semiconductor Fabrication Software Market The Semiconductor Fabrication Software market is on the brink of significant transformation, with projections indicating a remarkable growth of approximately USD 984.91 million from 2024 to 2028. This growth is primarily fueled by the rising complexity of semiconductor designs in conjunction with the impact of...

Continue Reading
Ohmyhome Prepares to Share Exciting Q3 2024 Growth Insights

Updated Category News Views 45

Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...

Continue Reading
Eli Lilly Prepares for Major Breast Cancer Data Presentation

Updated Category News Views 220

Introduction to Eli Lilly's Breast Cancer Initiatives At the upcoming San Antonio Breast Cancer Symposium (SABCS), Eli Lilly and Company (NYSE: LLY) is set to unveil groundbreaking data that enhances its portfolio in breast oncology. The symposium, running from December 9 to 12, serves as a platform for Lilly to highlight advancements in treatments for hormone...

Continue Reading